SEC Company Response from KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA) — Feb 27, 2009
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: Feb. 27, 2009 · CIK: 0001075880 · Accession: 0000950123-09-003665
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-29962
Letter
Re: Novogen Limited
February 27, 2009
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.W.
Washington, D.C. 20549
Ladies and Gentlemen:
Novogen Limited (the “Company”) is in receipt of the comment letter, dated February 24, 2009, from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “SEC”) with respect to the Company’s Annual Report on Form 20-F for the fiscal year ended June 30, 2008 (File No. 000-29962).
The Company will submit its written response to the comments raised by the Staff in the letter to the SEC via EDGAR no later than Tuesday, March 24, 2009.
NOVOGEN LIMITED
By:
/s/ David Seaton
Name:
David Seaton
Title:
Chief Financial Officer
Novogen Limited abn 37 063 259 754 140 Wicks Road, North Ryde NSW 2113, Australia Telephone +61 2 9878 0088 Facsimile +61 2 9878 0055 novogen@novogen.com www.novogen.com
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
February 27, 2009
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.W.
Washington, D.C. 20549
Re: Novogen Limited
Ladies and Gentlemen:
Novogen Limited (the “Company”) is in receipt of the comment letter, dated February 24,
2009, from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “SEC”)
with respect to the Company’s Annual Report on Form 20-F for the fiscal year ended June 30,
2008 (File No. 000-29962).
The Company will submit its written response to the comments raised by the Staff in the
letter to the SEC via EDGAR no later than Tuesday, March 24, 2009.
NOVOGEN LIMITED
By:
/s/ David Seaton
Name:
David Seaton
Title:
Chief Financial Officer
Novogen
Limited abn 37 063
259 754 140 Wicks Road, North Ryde NSW 2113, Australia
Telephone +61 2 9878 0088 Facsimile +61 2 9878 0055 novogen@novogen.com
www.novogen.com